Curevac Nv Stock Z Score
| CVAC Stock | USD 2.44 0.13 5.06% |
CureVac | Z Score |
CureVac NV Company Z Score Analysis
CureVac NV's Z-Score is a simple linear, multi-factor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..
| |||||||
| |||||||
| |||||||
| |||||||
|
CureVac Z Score Driver Correlations
Understanding the fundamental principles of building solid financial models for CureVac NV is extremely important. It helps to project a fair market value of CureVac Stock properly, considering its historical fundamentals such as Z Score. Since CureVac NV's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of CureVac NV's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of CureVac NV's interrelated accounts and indicators.
Click cells to compare fundamentals
To calculate a Z-Score, one would need to know a company's current working capital, its total assets and liabilities, and the amount of its latest earnings as well as earnings before interest and tax. Z-Scores can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with Z-Scores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a so-called 'grey area,' with scores of less than 1 indicating the highest probability of distress. Z Score is a used widely measure by financial auditors, accountants, money managers, loan processors, wealth advisers, and day traders. In the last 25 years, many financial models that utilize z-scores proved it to be successful as a predictor of corporate bankruptcy.
| Competition |
In accordance with the company's disclosures, CureVac NV has a Z Score of 0.0. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The z score for all United States stocks is 100.0% higher than that of the company.
CureVac NV Current Valuation Drivers
We derive many important indicators used in calculating different scores of CureVac NV from analyzing CureVac NV's financial statements. These drivers represent accounts that assess CureVac NV's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of CureVac NV's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 9.3B | 8.8B | 5.6B | 1.1B | 1.2B | 1.2B | |
| Enterprise Value | 9.3B | 7.5B | 4.9B | 614.9M | 707.2M | 671.8M |
CureVac NV Institutional Holders
Institutional Holdings refers to the ownership stake in CureVac NV that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of CureVac NV's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing CureVac NV's value.| Shares | Junked Platinum Investment Management Ltd | 2023-12-31 | 497.9 K | Eversept Partners, Llc | 2023-12-31 | 496.9 K | Norges Bank | 2023-12-31 | 308.7 K | Credit Suisse First Boston (csfb) | 2023-12-31 | 303.9 K | Adage Capital Partners Gp Llc | 2023-12-31 | 248.4 K | Geode Capital Management, Llc | 2023-12-31 | 202 K | Swiss National Bank | 2023-12-31 | 198.5 K | Susquehanna International Group, Llp | 2023-12-31 | 178.2 K | Ubs Group Ag | 2023-12-31 | 131.9 K | Citadel Advisors Llc | 2023-09-30 | 3.1 M | Ra Capital Management, Llc | 2023-12-31 | 2.7 M |
CureVac Fundamentals
| Return On Equity | -0.49 | ||||
| Return On Asset | -0.18 | ||||
| Operating Margin | (3.33) % | ||||
| Current Valuation | 153.45 M | ||||
| Shares Outstanding | 223.92 M | ||||
| Shares Owned By Insiders | 45.43 % | ||||
| Shares Owned By Institutions | 23.80 % | ||||
| Number Of Shares Shorted | 5.01 M | ||||
| Price To Book | 1.01 X | ||||
| Price To Sales | 15.20 X | ||||
| Revenue | 42.88 M | ||||
| Gross Profit | (91.55 M) | ||||
| EBITDA | (242.09 M) | ||||
| Net Income | (302.3 M) | ||||
| Cash And Equivalents | 540.87 M | ||||
| Cash Per Share | 2.85 X | ||||
| Total Debt | 42.09 M | ||||
| Debt To Equity | 0.07 % | ||||
| Current Ratio | 3.61 X | ||||
| Book Value Per Share | 2.69 X | ||||
| Cash Flow From Operations | (273.37 M) | ||||
| Short Ratio | 6.80 X | ||||
| Earnings Per Share | (1.56) X | ||||
| Price To Earnings To Growth | 0.07 X | ||||
| Target Price | 13.16 | ||||
| Number Of Employees | 904 | ||||
| Beta | 2.51 | ||||
| Market Capitalization | 575.48 M | ||||
| Total Asset | 860.47 M | ||||
| Retained Earnings | (1.31 B) | ||||
| Working Capital | 427.8 M | ||||
| Net Asset | 860.47 M |
About CureVac NV Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze CureVac NV's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of CureVac NV using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of CureVac NV based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with CureVac NV
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if CureVac NV position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in CureVac NV will appreciate offsetting losses from the drop in the long position's value.Moving together with CureVac Stock
| 0.79 | JNJ | Johnson Johnson Financial Report 18th of July 2024 | PairCorr |
Moving against CureVac Stock
| 0.77 | NUVB | Nuvation Bio Financial Report 2nd of May 2024 | PairCorr |
| 0.43 | JSPRW | Jasper Therapeutics | PairCorr |
| 0.42 | IOVA | Iovance Biotherapeutics Financial Report 14th of May 2024 | PairCorr |
The ability to find closely correlated positions to CureVac NV could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace CureVac NV when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back CureVac NV - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling CureVac NV to buy it.
The correlation of CureVac NV is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as CureVac NV moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if CureVac NV moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for CureVac NV can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out CureVac NV Piotroski F Score and CureVac NV Valuation analysis. For information on how to trade CureVac Stock refer to our How to Trade CureVac Stock guide.Note that the CureVac NV information on this page should be used as a complementary analysis to other CureVac NV's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the AI Investment Finder module to use AI to screen and filter profitable investment opportunities.
Complementary Tools for CureVac Stock analysis
When running CureVac NV's price analysis, check to measure CureVac NV's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CureVac NV is operating at the current time. Most of CureVac NV's value examination focuses on studying past and present price action to predict the probability of CureVac NV's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CureVac NV's price. Additionally, you may evaluate how the addition of CureVac NV to your portfolios can decrease your overall portfolio volatility.
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges |
Is CureVac NV's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CureVac NV. If investors know CureVac will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CureVac NV listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.56) | Revenue Per Share 0.201 | Quarterly Revenue Growth 0.47 | Return On Assets (0.18) | Return On Equity (0.49) |
The market value of CureVac NV is measured differently than its book value, which is the value of CureVac that is recorded on the company's balance sheet. Investors also form their own opinion of CureVac NV's value that differs from its market value or its book value, called intrinsic value, which is CureVac NV's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CureVac NV's market value can be influenced by many factors that don't directly affect CureVac NV's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CureVac NV's value and its price as these two are different measures arrived at by different means. Investors typically determine if CureVac NV is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CureVac NV's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.